98%
921
2 minutes
20
Background: Multiple system atrophy (MSA) is a relentlessly progressive neurodegenerative disorder with no cure. While therapeutic education programs (TEPs) benefit many chronic conditions, data in MSA are limited.
Objectives: To assess the feasibility and satisfaction of a mixed in-person/virtual TEP for early-stage MSA patients and caregivers.
Methods: A six-module, self-paced TEP was co-developed over 2 years by MSA healthcare professionals, patients, and education experts. A prospective pilot study enrolled recently diagnosed MSA patients (≤12 months) and caregivers. Primary outcomes were recruitment and retention rates. Secondary outcomes included disease progression (UMSARS I-II), health-related quality of life (Hr-QoL), compared to matched controls not enrolled in the TEP and patients' satisfaction.
Results: Fifteen patient-caregiver pairs were enrolled. Recruitment and retention rates were 44% and 86%, respectively; 78% of modules were completed (least consulted was disease progression). Disease severity and Hr-QoL worsened over 12 months, with no significant differences versus controls. Overall, 90% of participants were satisfied or very satisfied.
Conclusions: Our pilot study shows that a mixed TEP for MSA patients and familial caregivers is feasible and able to engage them over time.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/mdc3.70283 | DOI Listing |
BMC Oral Health
September 2025
Oral and Maxillofacial Radiology Department, Cairo university, Cairo, Egypt.
Aim: The purpose of this study was to assess the accuracy of a customized deep learning model based on CNN and U-Net for detecting and segmenting the second mesiobuccal canal (MB2) of maxillary first molar teeth on cone beam computed tomography (CBCT) scans.
Methodology: CBCT scans of 37 patients were imported into 3D slicer software to crop and segment the canals of the mesiobuccal (MB) root of the maxillary first molar. The annotated data were divided into two groups: 80% for training and validation and 20% for testing.
Neurodegener Dis Manag
September 2025
RWE Statistics, KMK Consulting, Inc, North Tower, Morristown, NJ, USA.
Background: Multiple system atrophy (MSA) is a progressive neurodegenerative disorder with diverse symptoms that complicate diagnosis. We aimed to characterize MSA-related symptoms, medications, and healthcare resource utilization (HCRU).
Research Design And Methods: This retrospective cohort study used a large US claims database.
Ann Rheum Dis
September 2025
Department of Pediatrics, Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.
Objectives: Juvenile dermatomyositis (JDM) is a heterogeneous autoimmune condition needing targeted treatment approaches and improved understanding of molecular mechanisms driving clinical phenotypes. We utilised exploratory proteomics from a longitudinal North American cohort of patients with new-onset JDM to identify biological pathways at disease onset and follow-up, tissue-specific disease activity, and myositis-specific autoantibody (MSA) status.
Methods: We measured 3072 plasma proteins (Olink panel) in 56 patients with JDM within 12 weeks of starting treatment (from the Childhood Arthritis and Rheumatology Research Alliance Registry and 3 additional sites) and 8 paediatric controls.
Cerebellum
September 2025
Department of Neurology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Multiple system atrophy (MSA) is a progressive, adult-onset neurodegenerative disorder involving autonomic failure, cerebellar ataxia, and parkinsonism. Patients often require invasive interventions, such as gastrostomy or tracheostomy, and sudden death is common. This study aimed to elucidate patterns of invasive treatment and identify risk factors for tracheostomy or sudden death within 5 years of onset.
View Article and Find Full Text PDFJ Neurol
September 2025
Department of Neurology, Seoul National University Hospital and Seoul National University College of Medicine, 101 Daehakro Jongno-gu, Seoul, 03080, Republic of Korea.
Speech disorders differ between Parkinson's disease (PD) and multiple system atrophy (MSA), but studies focusing on group differences based on syllables or including cerebellar ataxia (CA) are lacking until now. This cross-sectional study aimed to analyze syllable-based speech characteristics in patients with PD, MSA, and CA, as well as healthy controls, to determine their diagnostic utility. Speech samples were collected from 68 PD, 52 MSA, 23 CA, and 70 healthy controls.
View Article and Find Full Text PDF